Related Experiment Video

Updated: Apr 3, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.4K

Targeting fibroblast growth factor receptor pathway in breast cancer

Carmen Criscitiello1, Angela Esposito, Sabino De Placido

  • 1aDivision of Early Drug Development for Innovative Therapies, European Institute of Oncology, Milan bDipartimento di Medicina Clinica e Chirurgia, Università di Napoli Federico II, Napoli, Italy.

Current Opinion in Oncology
|September 24, 2015
PubMed
Abstract

Insights

Fibroblast growth factor receptor (FGFR) inhibitors show promise for breast cancer treatment by targeting aberrant FGFR signaling. Further research aims to optimize patient selection and develop next-generation inhibitors to overcome resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aberrant fibroblast growth factor receptor (FGFR) signaling plays a critical role in breast cancer pathogenesis.
  • Targeting FGFR has emerged as a promising therapeutic strategy in breast cancer treatment.

Purpose of the Study:

  • To critically review the recent literature on the rationale and potential role of FGFR inhibitors in breast cancer.
  • To summarize the current progress and future directions in FGFR-targeted therapy for breast cancer.

Main Methods:

  • Literature review of studies published in the last year.
  • Focus on preclinical and clinical investigations of FGFR inhibitors in breast cancer models and patients.

Main Results:

  • Substantial evidence supports the involvement of aberrant FGFR signaling in breast cancer.
  • Novel agents targeting FGF or FGFR have shown progress, with lucitanib demonstrating clinical activity, particularly in tumors with FGF aberrations.
  • Development of FGFR4 and covalent FGFR inhibitors may address resistance to current therapies.

Conclusions:

  • FGFR signaling inhibition is a growing area of investigation for breast cancer treatment.
  • Future research should focus on optimal patient selection and the development of next-generation FGFR inhibitors to overcome resistance mechanisms.

More Related Videos

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

6.8K
A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

5.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.9K
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K